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Introduction
Hypogonadotropic hypogonadism (HH) associated with ad-
renal hypoplasia congenita (AHC) is a very rare syndrome
caused by mutation of DAX1 (dosage-sensitive sex reversal-
adrenal hypoplasia congenita critical region on the X chro-
mosome) [19]. The DAX1 is located on the chromosome X
(Xp21.3–21.2) and contains two exons. It encodes a 470-
amino acid protein which belongs to the nuclear hormone
receptor superfamily (called DAX1). DAX1 is expressed in
the adrenal cortex, pituitary and hypothalamus, gonadal
cells such as Leydig and Sertoli cells, theca and granulosa
cells and in germ cells [15, 26].
Patients with HH due to DAX1 mutation exhibited azoo-
spermia [4, 5, 17, 24]. Results of spermatogenesis induction
using exogenous gonadotropin are unsatisfactory [4, 17, 24].
However, Frapsauce et al. [5] has recently presented the first
birth after successful assisted reproductive technique (ART)
using TESE-ICSI in a man with HH and AHC linked to a
DAX1 mutation. In this case, long period of gonadotropin
treatment allowed for development of few mature spermato-
zoa obtained from testicular biopsy and used for ICSI [5].
Here, we report clinical and immunohistochemical stud-
ies of patient with HH and AHC due to deletion of the
second exon of the DAX1 in order to induce spermatogen-
esis by gonadotropins treatment.
Materials and methods
Direct sequencing of DAX1 gene
Genomic DNA was extracted from peripheral blood leuko-
cytes using the salting-out method. Both exons of DAX1
gene were amplified by PCR using primers and conditions
described previously [22]. Direct sequencing of PCR prod-
ucts was performed using the BigDye™ Terminator Cycle
Sequencing Ready Reaction Kit 3.1 (Applied Biosystems).
Both primers were used for sequencing both strands. The
sequencing products were run on an ABI PRISM 3130
capillary automated sequencer (Applied Biosystems).
Immunohistochemistry
For immunohistochemical studies 15 representative sections
from the resected specimen were selected for each antigen
studied. Following biological markers were investigated:
gonadotropin receptors (LHR and FSHR), aromatase, estro-
gen receptors alpha and beta (ERα and ERβ), androgen
receptors (AR), and gap junction protein connexin 43
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(Cx43). The whole immunohistochemical procedure had
been described in detail previously [2, 8, 16]. In brief, to
achieve antigen retrieval slices were immersed in 10 mM
citrate buffer (pH 6.0) and heated for 2×5 min in the
microwave oven (750 W). Endogenous peroxidase activity
was blocked with 3 % H2O2 in methanol for 15 min and
nonspecific binding sites were blocked with 5 % nonim-
mune goat serum (v/v) for 30 min at room temperature.
Thereafter, testicular sections were incubated overnight at
4°C in a humidified chamber in the presence with the
following antibodies: rabbit polyclonal antibody against
LHR (1:100; BIOTREND Chemikalien GmbH, Köln, Ger-
many); goat polyclonal antibody against FSHR (N-20;
1:100; Santa Cruz Biotechnology, Inc., Santa Cruz, CA,
USA); rabbit polyclonal antibodies against AR(N-20;
1:1000; Santa Cruz Biotechnology) and against Cx43
(1:2000; Sigma-Aldrich, St Louis, MO, USA) as well as
mouse anti human monoclonal antibodies against P450 aro-
matase (1:100) and ERβ (1:50; Serotec, Düsseldorf, Ger-
many) and against ERα (1:100; Dako, Glostrup, Denmark).
Next, biotinylated secondary antibodies, horse anti-mouse
IgG, horse anti-goat IgG or goat anti-rabbit IgG for mono-
clonal or polyclonal antibodies, respectively (1:400; Vector
Labs., Burlingame, CA, USA) were applied. Finally, avidin-
biotinylated horseradish peroxidase complex (Vectastain
ABC Kit; 1:100; Vector Labs.) was used. After each step
in these procedures, sections were carefully rinsed with Tris-
buffered saline (TBS; 0.05 M Tris–HCl plus 0.15 M NaCl,
pH 7.6). Bound antibody was visualized with TBS contain-
ing 0.05 % 3,3′-diaminobenzidine and 0.07 % imidazole for
3–4 min. Sections were counterstained with Mayer’s hema-
toxylin. Thereafter, sections were dehydrated, cleared in xy-
lene, and mounted using DPX mounting medium (Fluka
Biochemica, Steinheim, Germany). The slides were processed
immunohistochemically at the same time with the same treat-
ment so the staining intensity among different sections of the
testis could be compared. Control sections included omission
of the primary antibody and substitution by an irrelevant IgG.
The sections were examined with a Leica DMR microscope
(Leica, Microsystems GmbH Wetzlar, Wetzlar, Germany)
using a Nomarski interference contrast. Experiments were
repeated three times and the expression of each marker was
assessed on the basis of visual examination of cytoplasmic or
nuclear localization in 10 different fields on serial sections.
Results
Patient
At the age of 32 years the male patient consulted due to
hypogonadotropic hypogonadism and infertility problems.
At the age of 8 years he was diagnosed with adrenal
hypoplasia congenita. Then substitution doses of 20 mg of
hydrocortisone treatment every day was applied. Moreover,
testosterone replacement therapy at a dose of 250 mg every
three weeks since 16 age was administered. The patient is
the only case with AHC and HH in his family. During
physical examination and medical history both testes
2 cm3 in dimension, penis 4 cm in length, eunuchoid body
proportions, height of 190 cm and hyperpigmentation of
skin were observed. Azoospermia was revealed in routine
semen analysis. Hormonal analysis showed: low LH level
(0,1 IU/L, N:1.5–9.3 IU/L), low FSH level (0.4 IU/L, N:
1.4–18.1 IU/L) and low testosterone level (0.2 ng/mL, N:
2.4–8.2 ng/mL). A GnRH test was performed. Plasma LH
concentrations did not increase after administration of phar-
macological doses of GnRH, while FSH concentrations
exhibited an increase to 1,3 mIU/mL in 60th minutes.
Previously in another clinic, in order to induce spermato-
genesis, patient was treated for 4 months with 1500 IU hCG
once a week, what we qualified as pretreatment. Then the
standard our clinic treatment for each patient diagnosed with
hypogonadotropic hypogonadism was applied. Patient was
stimulated as follows: for 5 days, human menopausal gonad-
otropin (HMG, Menopur, Ferring) was administered at a dose
of 75 IU FSH, and on the sixth day, hCG (Choragon, Ferring)
was given at a dose of 1500 IU. In subsequent months, testos-
terone level was as follows: 3.63, 4.53, 4.23, 4.34 ng/mL (N:
2,2–9,8 ng/mL), whereas estradiol level was as follows: 56, 65,
75, 82 pg/mL (N: 10–52 pg/mL). According to our experience,
after 4months of such therapy in ejaculate should appear single
spermatozoa, but semen analysis again showed azoospermia.
Open testicular biopsy in both testes was performed, after
obtain informed consent. Five samples from each testes were
received. Complete lack of spermatozoa was confirmed by
examination in light invertedmicroscope. Histological analysis
was carried out after haematoxylin-eosin (H+E) staining and
showed rare spermatogonia and spermatogenesis arrest. Tes-
ticular tissue was also fixed in 10 % (v/v) buffered formalde-
hyde solution for 48 h and then embedded in paraffin blocks at
56°C according to standard procedures for further immunohis-
tochemical examination. All studies have been approved by
the local Ethics Committee.
DAX1 gene mutation analysis
Genetic analysis, after obtain informed consent was conducted.
Direct sequencing ofDAX1 allowed to exclude the presence of
a point mutation in exon 1 DAX1gene. Deletion of exon 2 was
confirmed by PCR reaction using two different sets of primers.
Immunohistochemical studies
Positive immunohistochemical staining for each antigen was
found in all testicular sections with Leydig cell hypertrophy
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(Fig. 1a-g). Immunohistochemical analysis of the sections
revealed differential expression of gonadotropin receptors,
FSHR and LHR (Fig. 1a-b). Weak to moderate immunoex-
pression of FSHR was detected in the cytoplasm of some
Sertoli cells, whereas Leydig cells were immunonegative
(Fig. 1a). In contrast, in the sections stained for LHR, the
Leydig cell cytoplasmwas strongly immunopositive (Fig. 1b).
Similar cytoplasmic pattern of the staining was found in both
Leydig and Sertoli cells that displayed moderate to strong
immunoreactivity for aromatase (Fig. 1c). A few remained
germ cells were also immunopositive for aromatase. A strong
to very strong immunoexpression, nuclear in pattern, was
Fig. 1 a-g. Immunohistochemical localization of FSHR, LHR, aroma-
tase, ERα ERβ, AR, and Cx43 in well differentiated human Sertoli-
Leydig cell tumor. Immunostainings were performed using monoclonal
or polyclonal antibodies (for detail see the text) followed by anti-
mouse, anti-goat or anti-rabbit IgG, and ABC/HRP visualized by
DAB. Counterstaining with Mayer’s haematoxylin. Nomarski interfer-
ence contrast. Bars020 μm. a Weak to moderate staining for FSHR in
Sertoli cell cytoplasm (long arrows) and no staining in Leydig cells
(arrows) are visible. b Strong staining for LHR in Leydig cell cyto-
plasm (arrows) is visible. c Cytoplasmic pattern of the staining for
aromatase in Leydig cells (arrows) and Sertoli cells (long arrows) is
visible. Note a few remained germ cells also positively stained
(arrowheads). d Strong to very strong staining for ERα in nuclei of
Leydig cells is visible. No staining is seen in the other cells. eModerate
to strong staining for ERβ in a few remained germ cells is visible. f All
somatic cells are positively stained for AR. Note, weak staining in
nuclei of Sertoli cells (long arrows), moderate to strong in Leydig and
peritubular-myoid cells. g Strong to very strong signal for Cx43 be-
tween Sertoli and germ cells remained in the tubules (long arrows), and
between neighboring normal-looking Leydig cells is visible (arrows).
Note a diffuse pattern of the staining in hyperplastic Leydig cells
(arrowheads). The expression of all the antigens was undetectable
when the primary antibodies were omitted (see inserts in a-g)
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detected in all Leydig cells stained for ERα (Fig. 1d), whereas
moderate to strong immunoexpression of ERβ was found in a
few remained germ cells (Fig. 1e). Interestingly, all somatic
cells: Sertoli, Leydig and peritubular-myoid cells expressed
weak, moderate and strong staining for AR, respectively
(Fig. 1f). Immunoreactive protein Cx43, as a strong signal,
frequently linear in pattern, was present between Sertoli and
germ cells remained in the tubules. Moreover, a very strong
signal for Cx43 was also noted between neighboring normal-
looking Leydig cells, whereas in numerous hyperplastic Ley-
dig cells, the signal was of diffuse pattern (Fig. 1g). The
expression of all the antigens was undetectable when the
primary antibodies were omitted (see, inserts).
Discussion
In the present study, molecular analysis revealed deletion of
exon 2 of DAX1 gene in patient with adrenal insufficiency
and hypogonadotropic hypogonadisms. It has been shown
that DAX1 is a transcriptional repressor of SF-1, ER, AR,
PR, LHR1 [1, 7, 29], and repressor domain of DAX1 is
located at its carboxy-terminal end [23]. Deletion of exon 2
of DAX1 was first described by Salvi et al. [23]. The authors
reported that deletion of this exon decreases repressor func-
tion of DAX1 and also suggest that the deletion of second
exon of DAX1 has most dramatically affected the DAX1
function [23]. Furthermore in mice, deletion of the second
exon shows similar symptoms to those observed in humans.
On the other hand, Dax1 knock-out mouse model with
deletion of exon 2 revealed testis dysgenesis but normal
levels of testosterone and gonadotropins [28].
Immunohistochemical studies of gonadotropins treated tes-
tis show moderate to strong immunoreactivity for aromatase
in both Leydig and Sertoli cells as well as a strong immu-
noexpression in Leydig cells for ERα. In addition, high level
of estradiol in serum was noted. The DAX1 also represses
aromatase production and therefore the production of estrogen
[27]. Increased estrogen expression was described in the Ley-
dig cells of Dax1-deficient mice [9] and in mice with a partial
deletion in the long arm of the Y chromosome [11]. In case of
some patients with Sertoli cell-only syndrome increased intra-
testicular level of estradiol and aromatase expression has been
demonstrated [14], as well as strong aromatase expression in
Sertoli cells in patient with Klinefelter’s syndrome [12]. How-
ever, Brown et al. [4] did not find any evidence for over-
expression of aromatase in case of child with AHC. Authors
suggest that it may be due to the fact that the protein levels
were not high enough to be detected immunohistochemically
[4]. It seems that deletion of the second exon of DAX1 ob-
served in our patient caused absence of its repressor function,
and in consequence it leaded to aromatase overexpression and
increased estrogen production. Probably, this DAX1
dysfunction through indirect effect is able to disrupt spermato-
genesis even with normal testosterone level.
Recent data showed expression of DAX1 in germ cells
[15]. Postmortem testicular examination performed at a
23 days-old newborn with AHC and transversion in exon 2
of DAX1 gene demonstrated a well-defined testis cord con-
taining Sertoli cells, and germ cells surrounded by a interstitial
region [4]. These data show that DAX1 mutation does not
disturb normal fetal and neonatal testis development. In the
light of this observation, it seems likely that truncated DAX1
protein, due to DAX1 mutation, expressed in germ cells can
direct influence on spermatogenesis failure. Importantly,
according to Brown et al. [4] and Frapsauce et al. [5] the
process of decay of germ cells increases during time.
Additionally, we showed the presence of FSHR, LHR,
ERs, AR in patient testis, but expression of these receptors is
not sufficient to induce spermatogenesis by gonadotropins
treatment. This lack of spermatogenesis induction is proba-
bly associated with disturbed biological function of testis,
especially hyperplasia of Leydig cells and a possible defect
of Sertoli cells. Interestingly, strong immunostaining of
connexin 43 (Cx43) in testis was noted. The importance of
Cx43 expression during spermatogenesis has recently been
described in humans and several mammalian species [3, 6,
10, 13, 25]. Strong immunostaining, as observed in our case,
was detected in the membrane appositions between adjacent
Leydig cells in men with Klinefelter’s syndrome [13].
Bravo-Moreno et al. [3] showed that expression of Cx43
in Leydig cells is regulated in an age and functional-
dependent manner and suggests that its expression may be
participating in the developmental processes required for
adequate control of testosterone production and secretion.
Normal value of testosterone level after 4 months of gona-
dotropins treatment in our patient, may indicate an increased
metabolic activity of Leydig cells. This observation due to
strong signal for Cx43 in Leydig cells may suggests that
Cx43 plays important role in the control of Leydig cell
function. Furthermore, a strong immunoreactive signal of
Cx43 detected between Sertoli cells and remained germ
cells may show a role of Cx43 in communication between
these cells, as reported previously [3, 25].
To date, few biopsies of testis were performed [4, 5, 20, 21,
24]. Only the biopsy conducted by Frapsauce et al. [5]
revealed the presence of few spermatozoa. The first testicular
biopsy in patient with AHC and HH due to nucleotide deletion
of DAX1 gene was performed by Seminara et al. [24] after
7 years of low-dose hCG treatment showing few spermatogo-
nia but absence of spermatogenesis. In this patient gonadotro-
pin treatment was sufficient to testicular enlargement, but it
was not sufficient enough to induce spermatogenesis [24]. In
the case reported byOzisik et al. [21], testicular biopsy after 6-
month treatment in patient with DAX1 mutation in the N-
terminal end demonstrated disorganization of the normal
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seminiferous tubular structure, and moderate Leydig cell hy-
perplasia. Another analysis of testicular biopsy assessed by
Okuhara et al. [20] after 1 year treatment showed Sertoli cell
hypoplasia and no sperm formation.
Up to now, results concerning gonadotropin treatment to
the induction of spermatogenesis are unsatisfactory [4, 17,
24]. In the case of our patient, testicular biopsy was performed
after 4 months of stimulation and showed lack of spermato-
zoa. However, Frapsauce et al. [5] was recently reported birth
after TESE-ICSI from a man with nonsense mutation in the C-
terminal end of DAX1 and spermatogenesis induced by
20 months of gonadotropins treatment. Authors showed that
some tubules may contain focal complete spermatogenesis
and some spermatozoa may be obtained by testicular biopsy,
despite the presence of severe hypospermatogenesis with
germ cell arrested at the spermatocyte stage [5]. This report,
was emphasized by the authors, gives hope for patients with a
mutation inDAX1 gene after a long treatment with exogenous
gonadotropins to obtain children. On the other hand, Manto-
vani et al. [18] reported that even the year-long gonadotropin
treatment did not induce spermatogenesis. However, none of
their patients underwent a testicular biopsy, and it is not
possible to exclude the presence of a small number of sper-
matozoa in testis. In order to successful induction of sper-
matogenesis patients with hypogonadism and mutation in
DAX1 gene should undergo long period of treatment before
testicular biopsy [5].
Overall, in the study presented herein we showed over-
expression of aromatase in Leydig and Sertoli cells in man
with hypogonadotropic hypogonadism associated with adre-
nal hypoplasia congenita after gonadotropins treatment. The
presence of FSHR, LHR, ERs, AR and Cx43 in patient testis
suggest that system is functionally efficient and it should be
sufficient to induce spermatogenesis. However, our results
strongly suggest interrelation between aromatase overexpres-
sion leading to increased estrogen production and failure of
spermatogenesis induction. In order to confirm and explain
our findings more detailed studies need to be undertaken.
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